Meredith Barnett
Family · Manchester, TNNPI 1992194526
Payments from drug & device makers
Across 153 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$449
- Biohaven Pharmaceutical Holding Company Ltd.$181
- Boehringer Ingelheim$170
- Novo Nordisk$163
- Takeda Pharmaceuticals U.S.A., Inc.$152
- Novartis$147
- plus $2K from 28 others
What the payments were for
- Consulting fees$201%
- Food & beverage$2,78299%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $449 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $181 |
| Boehringer Ingelheim | 10 | $170 |
| Novo Nordisk | 10 | $163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $152 |
| Novartis | 9 | $147 |
| AstraZeneca(2 entities) | 9 | $131 |
| Amgen | 8 | $127 |
| CSL Behring | 4 | $107 |
| GSK | 7 | $105 |
| TG Therapeutics, Inc. | 1 | $97 |
| Dexcom, Inc. | 5 | $89 |
| Johnson & Johnson | 5 | $87 |
| Boston Scientific | 2 | $85 |
| Lundbeck LLC | 4 | $81 |
| Lilly USA, LLC | 5 | $79 |
| Merck | 4 | $71 |
| Biohaven Pharmaceuticals, Inc. | 3 | $59 |
| Pfizer | 4 | $57 |
| Genentech USA, Inc. | 2 | $41 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| Eisai Inc. | 2 | $36 |
| Nestle Healthcare Nutrition Inc. | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $29 |
| Corcept Therapeutics | 2 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $25 |
| ADMA Biomanufacturing LLC | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| IBSA Pharma Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Insulet Corporation | 1 | $14 |
| Astellas Pharma US Inc | 1 | $11 |
How this compares
$2,803 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other family in Manchester
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.